Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.4.0.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Apr. 30, 2016
Apr. 30, 2015
Apr. 30, 2016
Apr. 30, 2015
Revenues:        
Clinical laboratory services $ 18,162 $ 15,657 $ 52,775 $ 46,204
Product revenues 8,001 7,906 22,266 23,631
Royalty and license fee income 270 423 1,129 2,067
Total revenues 26,433 23,986 76,170 71,902
Operating expenses:        
Cost of clinical laboratory services 11,142 9,724 32,009 29,100
Cost of product revenues 3,846 3,779 10,663 11,292
Research and development 882 809 2,610 2,434
Selling, general, and administrative 10,869 10,146 32,374 30,101
Provision for uncollectible accounts receivable 576 589 1,739 1,731
Legal fee expense 1,632 1,955 5,644 7,225
Legal settlements, net   (170) (18,450) (170)
Total operating expenses 28,947 26,832 66,589 81,713
Operating Income (loss) (2,514) (2,846) 9,581 (9,811)
Other income (expense):        
Interest (40) (58) (122) (176)
Other 22 26 87 28
Foreign exchange gain (loss) 419 (125) (99) (856)
Income (loss) before income taxes (2,113) (3,003) 9,447 (10,815)
(Provision) benefit for income taxes (2) 96 (296) 88
Net income (loss) $ (2,115) $ (2,907) $ 9,151 $ (10,727)
Net income (loss) per common share:        
Basic (in Dollars per share) $ (0.05) $ (0.06) $ 0.20 $ (0.24)
Diluted (in Dollars per share) $ (0.05) $ (0.06) $ 0.20 $ (0.24)
Weighted average common shares outstanding:        
Basic (in Shares) 46,201 45,797 46,115 45,120
Diluted (in Shares) 46,201 45,797 46,450 45,120